Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Depreciation & Amortization (CF) (2016 - 2025)

Lexaria Bioscience's Depreciation & Amortization (CF) history spans 11 years, with the latest figure at $16866.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 49.19% year-over-year to $16866.0; the TTM value through Nov 2025 reached -$16329.0, down 120.27%, while the annual FY2024 figure was $76153.0, 47.62% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $16866.0 at Lexaria Bioscience, up from -$66427.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $70928.0 in Q3 2023 and bottomed at -$66427.0 in Q3 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $24871.0 (2022), against an average of $21246.2.
  • The largest annual shift saw Depreciation & Amortization (CF) soared 186.79% in 2023 before it crashed 505.78% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $27930.0 in 2021, then dropped by 11.46% to $24730.0 in 2022, then increased by 16.37% to $28778.0 in 2023, then rose by 15.35% to $33195.0 in 2024, then tumbled by 49.19% to $16866.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Depreciation & Amortization (CF) are $16866.0 (Q4 2025), -$66427.0 (Q3 2025), and $30955.0 (Q2 2025).